| 1.73 0.1 (6.13%) | 01-16 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.29 | 1-year : | 2.68 |
| Resists | First : | 1.96 | Second : | 2.29 |
| Pivot price | 1.57 |
|||
| Supports | First : | 1.41 | Second : | 1.18 |
| MAs | MA(5) : | 1.57 |
MA(20) : | 1.63 |
| MA(100) : | 1.8 |
MA(250) : | 4.58 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 53.7 |
D(3) : | 34.1 |
| RSI | RSI(14): 55 |
|||
| 52-week | High : | 11.64 | Low : | 1.37 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ INMB ] has closed below upper band by 1.0%. Bollinger Bands are 36.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.75 - 1.76 | 1.76 - 1.76 |
| Low: | 1.57 - 1.58 | 1.58 - 1.59 |
| Close: | 1.72 - 1.73 | 1.73 - 1.74 |
INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on developing drugs to reprogram the patient's innate immune system to treat disease. The company develops and commercializes product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. Its development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma and patients with high-risk myelodysplastic syndrome; INB03, an immunotherapy that treats patients with hematologic malignancies and solid tumors; and XPro1595 for the treatment of Alzheimer's disease. The company has license agreements with Xencor, Inc.; Immune Ventures, LLC; University of Pittsburg; and University College London. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.
Sat, 17 Jan 2026
INmune Bio Stock Slumps After Alzheimer’s Drug Falls Short In Mid-Stage Trial - MSN
Wed, 03 Dec 2025
Could INmune Bio Unlock Value With Upcoming Regulatory Catalysts And Clinical Readouts? - RTTNews
Mon, 01 Dec 2025
INmune Bio stock falls after new Alzheimer’s trial data - Investing.com
Tue, 18 Nov 2025
INmune Bio (INMB) plans XPro1595 Phase 2 Alzheimer’s and EMACC talks at 18th CTAD - Stock Titan
Thu, 06 Nov 2025
INmune Bio (INMB) Could Find a Support Soon, Here's Why You Should Buy the Stock Now - Nasdaq
Thu, 30 Oct 2025
INmune Bio Inc (INMB) Q3 2025 Earnings Call Highlights: Regulatory Progress and Financial ... - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 27 (M) |
| Held by Insiders | 2.061e+007 (%) |
| Held by Institutions | 17 (%) |
| Shares Short | 3,450 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -69 % |
| Return on Assets (ttm) | 724 % |
| Return on Equity (ttm) | -50.6 % |
| Qtrly Rev. Growth | 50000 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | -169.32 |
| EBITDA (p.s.) | 54347.8 |
| Qtrly Earnings Growth | -2.1 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -31 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.02 |
| Price to Cash Flow | 1.67 |
| Dividend | 0 |
| Forward Dividend | 3.42e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|